-
摘要: 射血分数保留的心力衰竭(HFpEF)约占目前心力衰竭(HF)的一半,HFpEF的临床特征是劳力性呼吸困难,一般是由于运动过程中左房压力异常升高所致,且HF患者左房充盈压升高与预后不良息息相关。在这种情况下,单向小型房间隔缺损的存在可以防止左房压力的极端增加,防止持续的肺充血和急性失代偿,而不会造成严重的右房并发症(肺高压)。因此,通过建立单向的左向右房间分流进行左房减压已成为HFpEF患者的一种新的治疗策略。
-
关键词:
- 心力衰竭 /
- 射血分数保留的心力衰竭 /
- 心房分流 /
- 器械治疗
Abstract: Heart failure with preserved ejection fraction(HFpEF) accounts for about half of current heart failure.HFpEF is clinically characterized by exertional dyspnea,which is usually caused by abnormally increased left atrial pressure during exercise.Moreover,increased left atrial filling pressure in heart failure patients is associated with poor prognosis.In this case,the presence of a unidirectional small atrial septal defect can prevent the extreme increase in left atrial pressure and prevent sustained pulmonary congestion and acute decompensation without causing severe right ventricular complications(pulmonary hypertension).Therefore,left atrial decompression by establishing one-way left to right ventricular shunt has become a new treatment strategy for HFpEF.-
Key words:
- heart failure /
- HFpEF /
- atrial shunt /
- instrument therapy
-
-
[1] Benjamin EJ,Virani SS,Callaway CW,et al.Heart Disease and Stroke Statistics-2018 Update:A Report From the American Heart Association[J].Circulation,2018,137(12):e67-e492.
[2] Roger VL,Weston SA,Redfield MM,et al.Trends in Heart Failure Incidence and Survival in a Community-Based Population[J].JAMA,2004,292(3):344-350.
[3] Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,62(16):e147-e239.
[4] Dickstein K,Cohen-Solal A,Filippatos G,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)[J].Eur J Heart Fail,2008,10(10):933-989.
[5] McMurray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J].Eur J Heart Fail,2012,14(8):803-869.
[6] Owan TE,Hodge DO,Herges RM,et al.Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction[J].N Engl J Med,2006,355(3):251-259.
[7] Bhatia RS,Tu JV,Lee DS,et al.Outcome of heart failure with preserved ejection fraction in a population-based study[J].N Engl J Med,2006,355(3):260-269.
[8] Steinberg BA,Zhao X,Heidenreich PA,et al.Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction:prevalence,therapies,and outcomes[J].Circulation,2012,126(1):65-75.
[9] Oktay AA,Rich JD,Shah SJ.The emerging epidemic of heart failure with preserved ejection fraction[J].Curr Heart Fail Rep,2013,10(4):401-410.
[10] Beale AL,Meyer P,Marwick TH,et al.Sex Differences in Cardiovascular Pathophysiology:Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction[J].Circulation,2018,138(2):198-205.
[11] Pitt B,Pfeffer MA,Assmann SF,et al.Spironolactone for heart failure with preserved ejection fraction[J].N Engl J Med,2014,370(15):1383-1392.
[12] Cleland JG,Tendera M,Adamus J,et al.The perindopril in elderly people with chronic heart failure (PEP-CHF) study[J].Eur Heart J,2006,27(19):2338-2345.
[13] Abraham WT,Fisher WG,Smith AL,et al.Cardiac resynchronization in chronic heart failure[J].N Engl J Med,2002,346(24):1845-1853.
[14] Cazeau S,Leclercq C,Lavergne T,et al.Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay[J].N Engl J Med,2001,344(12):873-880.
[15] Abraham WT,Adamson PB,Bourge RC,et al.Wireless pulmonary artery haemodynamic monitoring in chronic heart failure:a randomised controlled trial[J].The Lancet,2011,377(9766):658-666
[16] Krum H,Abraham WT.Heart failure[J].Lancet,2009,373(9667):941-955.
[17] Adams KF Jr,Fonarow GC,Emerman CL,et al.Characteristics and outcomes of patients hospitalized for heart failure in the United States:rationale,design,and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)[J].Am Heart J,2005,149(2):209-216.
[18] Andersen MJ,Ersb ll M,Bro-Jeppesen J,et al.Exercise hemodynamics in patients with and without diastolic dysfunction and preserved ejection fraction after myocardial infarction[J].Circ Heart Fail,2012,5(4):444-451.
[19] Kaye D,Shah SJ,Borlaug BA,et al.Effects of an interatrial shunt on rest and exercise hemodynamics:results of a computer simulation in heart failure[J].J Card Fail,2014,20(3):212-221.
[20] Webb G,Gatzoulis MA.Atrial septal defects in the adult:recent progress and overview[J].Circulation,2006,114(15):1645-1653.
[21] Søndergaard L,Reddy V,Kaye D,et al.Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure[J].Eur J Heart Fail,2014,16(7):796-801.
[22] Malek F,Neuzil P,Gustafsson F,et al.Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant[J].Int J Cardiol,2015,187:227-228.
[23] Hasenfuβ G,Hayward C,Burkhoff D,et al.A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF):a multicentre,open-label,single-arm,phase 1 trial[J].Lancet,2016,387(10025):1298-1304.
[24] Dorfs S,Zeh W,Hochholzer W,et al.Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction[J].Eur Heart J,2014,35(44):3103-3112.
[25] Kaye DM,Hasenfuβ G,Neuzil P,et al.One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction[J].Circ Heart Fail,2016,9(12).pii:e003662.
[26] Feldman T,Mauri L,Kahwash R,et al.Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]):A Phase 2,Randomized,Sham-Controlled Trial[J].Circulation,2018,137(4):364-375.
[27] Del Trigo M,Bergeron S,Bernier M,et al.Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction:a safety and proof-of-principle cohort study[J].Lancet,2016,387(10025):1290-1297.
[28] Amat-Santos IJ,Bergeron S,Bernier M,et al.Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure:first-in-man experience with the V-Wave device[J].EuroIntervention,2015,10(9):1127-1131.
[29] Hlatky MA,Boineau RE,Higginbotham MB,et al.A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index)[J].Am J Cardiol,1989.64(10):651-654.
[30] Green CP,Porter CB,Bresnahan DR,et al.,Development and evaluation of the Kansas City Cardiomyopathy Questionnaire:a new health status measure for heart failure[J].J Am Coll Cardiol,2000,35(5):1245-1255.
[31] Dai S,Manoucheri M,Gui J,et al.Kansas City Cardiomyopathy Questionnaire Utility in Prediction of 30-Day Readmission Rate in Patients with Chronic Heart Failure[J].Cardiol Res Pract,2016,2016:4571201.
[32] Rodés-Cabau J,Bernier M,Amat-Santos IJ,et al.Interatrial Shunting for Heart Failure:Early and Late Results From the First-in-Human Experience With the V-Wave System[J].JACC Cardiovasc Interv,2018.11(22):2300-2310.
[33] Guimarães L,Bergeron S,Bernier M,et al.Initial Experience with the Second-Generation V-Wave Shunt for Treating Patients with Chronic Heart Failure[J].EuroIntervention,2019.[Epub ahead of print].
[34] Paitazoglou C,Özdemir R,Pfister R,et al.The AFR-PRELIEVE trial:a prospective,non-randomised,pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction[J].EuroIntervention,2019,15(5):403-410.
-
计量
- 文章访问数: 83
- PDF下载数: 4
- 施引文献: 0
下载: